Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 4/20 | 0.61 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 10/20 | 0.42 |
| ▸ | BRAF | P15056 | 8/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14656301 | 0.85 | GCK (0.59) | GCKP2RX3KDRBRAFSRC | |
| SCHEMBL29788821 | 0.85 | GCK (0.61) | GCKKDRBRAF | |
| SCHEMBL2555530 | 0.85 | GCK (0.61) | GCKKDRBRAF | |
| SCHEMBL2548367 | 0.84 | GCK (0.44) | GCKP2RX3KDRBRAF | |
| SCHEMBL2554803 | 0.83 | GCK (0.65) | GCKSRCSYKGSK3A | |
| SCHEMBL2548106 | 0.82 | GCK (0.57) | GCKP2RX3KDRBRAF | |
| SCHEMBL12283891 | 0.82 | GCK (0.43) | GCKMAP4K1 | |
| SCHEMBL14656568 | 0.80 | AXL (0.43) | GCKKDRBRAF | |
| SCHEMBL2551326 | 0.80 | GCK (0.40) | GCKKDRBRAFSRCSYK | |
| SCHEMBL4325929 | 0.79 | GCK (0.73) | GCKKDRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-9771354-B2 | Pyrazole p38 map kinase inhibitors | RESPIVERT LTD. (GB) | 2017-09-26 | — | — | US | disclosed |
| US-9771354-B2 | Pyrazole p38 map kinase inhibitors | RESPIVERT LTD. (GB) | 2017-09-26 | — | — | US | disclosed |
| US-20160130256-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2016-05-12 | — | — | US | disclosed |
| US-20160130256-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2016-05-12 | — | — | US | disclosed |
| EP-2556065-B1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2014-12-17 | — | — | EP | disclosed |
| EP-2556065-B1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2014-12-17 | — | — | EP | disclosed |
| EP-2556065-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2013-02-13 | — | — | EP | disclosed |
| US-20130029990-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130029990-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2011121366-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011121366-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362208-A1 | NOVEL COMPOUNDS | ARG1, IL1B, LTB4R | GCK 2818/4885MAP4K1 3587/4885P2RX3 232/4885 |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | MAPK1, MAP3K1, MAPK3 | GCK 1134/4885MAP4K1 24/4885P2RX3 124/4885 |
| US-20160130256-A1 | NOVEL COMPOUNDS | ARG1, IL1B, LTB4R | GCK 2818/4885MAP4K1 3587/4885P2RX3 232/4885 |
| US-20130029990-A1 | PYRAZOLE P38 MAP KINASE INHIBITORS | MAPK1, MAP3K1, MAPK3 | GCK 1138/4885MAP4K1 25/4885P2RX3 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.